Medtronic (NYSE: MDT) announced today that it appointed Linnea Burman as the new SVP and president of its Neurovascular business unit.
The medtech giant selected Burman to succeed Dan Volz, who will take on the new role of SVP, global commercial transformation. In this new role, Volz leads a company-wide effort to modernize and transform commercial strategies and go-to-market approaches.
Burman’s responsibilities in her new role include portfolio strategy, product development and commercial execution within the unit focused on stroke treatment. She reports to Brett Wall, EVP and president of the Medtronic Neuroscience portfolio.
“Linnea is a strategic and visionary leader who maintains a customer-first mindset while building and developing high-performing teams,” said Wall. “Her strong record of success, deep medtech industry knowledge, and previous experience in stroke demonstrate her business acumen and underscore the commitment to making a meaningful impact on patient outcomes. I have the utmost confidence the Neurovascular business will continue to thrive under her leadership.”
More about new Medtronic Neurovascular president Linnea Burman
Burman brings more than 20 years of experience managing global teams within the medtech industry. Previously, she served as VP and GM of enabling technologies within Medtronic’s Cranial and Spine Technologies (CST) business. She helped establish CST, drive commercial growth strategies and more.
Throughout her time at Medtronic, Burman played a pivotal role in elevating market development for a post-stroke spasticity indication in the drug delivery business. She brings close relationships with renowned stroke neurologitsts, influential stroke associations and dedicated patient advocacy groups.
On top of business responsibilities, Burman leads inclusive and supportive professional networks as well. She serves as an executive chair for the ASPIRE network, which champions the growth, development and success of women field employees at Medtronic. She’s also engaged in the Medtronic Women’s Network (MWN). While in the CST unit, she founded the ET Enablers, a global employee group dedicated to enhancing two-way communication and collaboration.
“I’m continually inspired by Medtronic’s dedication to innovation and honored to step into my new role in the Neurovascular business that has transformed the stroke treatment landscape unlike any other medtech firm,” said Burman. “I look forward to working with my new team to build on our proven track record of advancing stroke care practices, fostering new partnerships within the neurovascular community, and developing effective therapies grounded in compelling clinical evidence.”
The company also names a new president of Pelvic Health unit
Medtronic also announced that Emily Elswick, previously VP, office of the CEO, is now president of Pelvic Health. In this role, she also serves on the Neurosciences leadership team.
“Emily is a bold, purpose-driven leader who is known for making courageous decisions to better serve patients,” said Wall. “Her deep commercial experience makes her uniquely qualified to lead Pelvic Health in an increasingly competitive and dynamic market. Pelvic Health has shown a great deal of positive momentum and I look forward to seeing where it will go with Emily at the helm.”
Elswick has more than 26 years of experience leading medtech and telecommunications outfits, with 20 years spent at Medtronic. Her previous positions focused on implementing enterprise-wide strategic initiatives, including coordinating the annual strategic planning and capital allocation processes.
She also served as VP and GM of Medtronic Lung Health and Visualization. There, she led a cross-functional global organization dedicated to developing minimally invasive diagnostic and therapeutic solutions.
Additionally, Elswick supports inclusion, diversity and equity initiatives both inside and outside of Medtronic. She also sits on the MWN leadership team and serves as chair of the MWN Hub Operations team.
